podcast.de
Anmeldung
Anmeldung Registrierung
Auto Hell Dunkel
Erweiterte Suche
  1. Startseite
  2. Podcasts
  3. Medizin - Open Access LMU - Teil 20/22 Podcast
  4. The price of tumor control
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking
antibody, has been approved for the treatment of metastatic
melanoma and induces adverse events (AE) in up to 64% of patients.
Treatment algorithms for the management of common
ipilimumab-induced AEs have lead to a reduction of morbidity, e.g.
due to bowel perforations. However, the spectrum of less common AEs
is expanding as ipilimumab is increasingly applied. Stringent
recognition and management of AEs will reduce drug-induced
morbidity and costs, and thus, positively impact the cost-benefit
ratio of the drug. To facilitate timely identification and adequate
management data on rare AEs were analyzed at 19 skin cancer
centers. Patient files (n = 752) were screened for rare
ipilimumab-associated AEs. A total of 120 AEs, some of which were
life-threatening or even fatal, were reported and summarized by
organ system describing the most instructive cases in detail.
Previously unreported AEs like drug rash with eosinophilia and
systemic symptoms (DRESS), granulomatous inflammation of the
central nervous system, and aseptic meningitis, were documented.
Obstacles included patientś delay in reporting symptoms and the
differentiation of steroid-induced from ipilimumab-induced AEs
under steroid treatment. Importantly, response rate was high in
this patient population with tumor regression in 30.9% and a tumor
control rate of 61.8% in stage IV melanoma patients despite the
fact that some patients received only two of four recommended
ipilimumab infusions. This suggests that ipilimumab-induced
antitumor responses can have an early onset and that severe
autoimmune reactions may reflect overtreatment. The wide spectrum
of ipilimumab-induced AEs demands doctor and patient awareness to
reduce morbidity and treatment costs and true ipilimumab success is
dictated by both objective tumor responses and controlling severe
side effects.

Weitere Episoden

Persistent nasal methicillin-resistant staphylococcus aureus carriage in hemodialysis outpatients: a predictor of worse outcome

Persistent nasal methicillin-resistant staphylococcus aureus carriage in hemodialysis outpatients: a predictor of worse outcome

vor 13 Jahren
Dose-volumetric parameters and prediction of severe acute esophagitis in patients with locally-advanced non small-cell lung cancer treated with neoadjuvant concurrent hyperfractionated-accelerated chemoradiotherapy

Dose-volumetric parameters and prediction of severe acute esophagitis in patients with locally-advanced non small-cell lung cancer treated with neoadjuvant concurrent hyperfractionated-accelerated chemoradiotherapy

vor 13 Jahren
Factors influencing the efficiency of generating genetically engineered pigs by nuclear transfer: multi-factorial analysis of a large data set

Factors influencing the efficiency of generating genetically engineered pigs by nuclear transfer: multi-factorial analysis of a large data set

vor 13 Jahren
Genome-wide linkage analysis of congenital heart defects using MOD score analysis identifies two novel loci

Genome-wide linkage analysis of congenital heart defects using MOD score analysis identifies two novel loci

vor 13 Jahren
Comparison of symptomatic and asymptomatic atherosclerotic carotid plaques using parallel imaging and 3 T black-blood in vivo CMR

Comparison of symptomatic and asymptomatic atherosclerotic carotid plaques using parallel imaging and 3 T black-blood in vivo CMR

vor 13 Jahren
Alle Episoden anzeigen
In Podcasts werben
Schalte jetzt Werbung in Podcasts.
Episode melden

„The price of tumor control“

Worum geht es? Danach fragen wir noch nach dem Grund.

Abonnenten

Teilen

Mein Archiv

Deine Privatkopie der Folgen, die du nicht verlieren willst.

Podcast-Folgen verschwinden. Feeds werden auf die letzten Episoden gekürzt, Hoster räumen alte Dateien ab, Formate wechseln den Anbieter und lassen ihr Archiv zurück. Mit „Mein Archiv“ sichert podcast.de die Folgen deiner Podcasts für dich — angefangen bei den ältesten, denn die sind zuerst weg.

  • Deine gesicherten Folgen bleiben hörbar, auch wenn das Original offline geht.
  • Auch Folgen, die im heutigen Feed gar nicht mehr stehen — podcast.de kennt sie noch.
  • Herunterladen bleibt möglich, solange die Folge beim Podcaster liegt. Der zählt seine Abrufe wie bisher.
Startet bald

Sei beim Start von Mein Archiv dabei

Mein Archiv ist fast fertig. Trag dich ein, dann bekommst du eine E-Mail, sobald es losgeht – und bist von Anfang an dabei. Wir schreiben dir nur zum Start, keine Werbung, keine Weitergabe deiner Daten.

Du bekommst zuerst eine Bestätigungsmail. Abmelden geht jederzeit. Datenschutz